RightFit
Not yet recruitingNot applicable

Scalable Behavioral Program for Weight Loss Maintenance After GLP-1 and Anti-Obesity Medication Discontinuation

Pilot Trial of a Scalable Behavioral Program for Weight Loss Maintenance After GLP-1 and Anti-Obesity Medication Discontinuation

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Time periods mentioned: 6 months

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "Participants will be randomized using a 2 × 2 × 2 factorial design and followed for six months."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests a program to help adults keep weight off after stopping GLP-1 or other weight loss medicines. It includes a 10-week core program and tests added support: meals tailored to medical needs, a YMCA membership, and a mind-based program. The study lasts 6 months and is for adults who lost at least 15% of their starting weight with weight loss medicine.

This study is a single-site, pilot randomized factorial trial designed to evaluate the feasibility, acceptability, participant perceptions and preliminary effects of a multi-component behavioral intervention to support weight loss maintenance following discontinuation of GLP-1 and other anti-obesity medications. The intervention includes a standardized 10-week foundational weight loss maintenance program combined with candidate support components, including medically tailored meals, YMCA membership, and a structured mind-based program. Participants will be randomized using a 2 × 2 × 2 factorial design and followed for six months. Findings from this pilot study will inform optimization of a scalable intervention for future clinical trials.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Be age 18 or older and able to give informed consent, meaning you understand and agree to join.
  • Have lost at least 15% of your starting weight using weight loss medicine.
  • Have stopped weight loss medicine within the past 4 weeks, or plan to stop before being assigned to a study group.
  • Have gained back no more than 3 kilograms (about 6.6 pounds) in the past 3 months.
  • Be willing and able to join the 6-month program, including the 10-week core program.
  • Be willing to complete study checks at the start, 3 months, and 6 months, including required in-person visits.
  • Have medical approval for moderate exercise, diet changes, and mind-based practices.
  • Have reliable internet for online sessions and data collection, and enough English skills to complete study tasks.

Who can't join

  • Have a health condition that makes exercise, diet changes, or mind-based practices unsafe, such as uncontrolled high blood pressure or seizures not managed with medical care.
  • Have a current mental health condition that affects safety or participation, such as untreated major depression, a substance use disorder, or loss of touch with reality.
  • Be pregnant, breastfeeding, or planning to become pregnant during the study.
  • Be in another structured program to lose weight or keep weight off.
  • Keep using weight loss medicine after being assigned to a study group.
  • Plan to start medicines or treatments that may greatly affect weight during the study.
  • Be unable to attend required visits, join online sessions, or provide data remotely.
  • Have any condition that the study team believes could make participation unsafe or affect the study’s results.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Age 18 years or older * Loss of ≥15% of initial body weight using anti-obesity medication * Discontinued anti-obesity medication within the past 4 weeks or planning to discontinue prior to randomization * ≤3 kg weight regain within the past 3 months * Willing and able to participate in a 6-month behavioral intervention, including a 10-week foundational program * Willing to complete study assessments at baseline, 3 months, and 6 months, including required in-person visits * Medical clearance for participation in moderate physical activity, dietary modification, and mind-based practices * Access to reliable internet for participation in virtual sessions and remote data collection * English fluency sufficient to complete study procedures * Able to provide informed consent Exclusion Criteria: * Medical conditions that would preclude safe participation in physical activity, dietary changes, or mind-based practices (e.g., unstable cardiovascular disease, uncontrolled hypertension, severe orthopedic limitations, or seizure disorders not medically managed) * Active psychiatric conditions that would interfere with participation or safety (e.g., untreated major depression, active substance use disorder, or psychosis) * Pregnancy, breastfeeding, or plans to become pregnant during the study period * Current participation in another structured weight loss or weight maintenance program * Continued use of anti-obesity medication after randomization * Plans to initiate medications or treatments that may significantly affect body weight during the study period * Inability to attend required study visits or participate in virtual sessions and remote data collection * Any condition that, in the opinion of the investigators, would compromise participant safety or study integrity

Study sites (1)

AL